Showing results (1-10 of 385) with videos related to
Sort By:
Pageof 39
Revue Medicale Suisse|March 11, 2026
[Rheumatoid arthritis pathogenesis. From susceptibility to autoimmunity, and arthritis]Matthias Jarlborg, Cem Gabay, Axel FinckhCytokine|October 23, 2021
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the jointsMatthias Jarlborg, Cem GabayCurrent Opinion in Rheumatology|April 5, 2008
At the horizon of innovative therapy in rheumatology: new biologic agentsAxel Finckh, Cem GabayThe Journal of Rheumatology|July 17, 2014
Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?Elena Ciubotariu, Cem Gabay, Axel Finckh, et al.Revue Medicale De La Suisse Romande|November 24, 2004
[Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis]Axel Finckh, Cem Gabay, Pierre-André GuerneRheumatology (Oxford, England)|April 30, 2015
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management RegistryCem Gabay, Myriam Riek, Almut Scherer, et al.Therapeutics and Clinical Risk Management|May 14, 2008
A systematic review of infliximab in the treatment of early rheumatoid arthritisSophie Martin Du Pan, Cem Gabay, Axel FinckhArthritis Research & Therapy|May 8, 2020
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritisMatthias Jarlborg, Delphine S Courvoisier, Céline Lamacchia, et al.Nature Reviews. Rheumatology|July 9, 2026
Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseasesCem Gabay, Charlotte Girard-Guyonvarc'h, Laurie Vaillant, et al.Revue Medicale Suisse|March 8, 2018
[Microbiota and inflammatory rheumatisms]Matthias Jarlborg, Deshiré Alpizar-Rodriguez, Athan Baillet, et al.Pageof 39